Cargando…

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

(1) Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney disease in different disease settings. The aim of this study was to investigate a possible link between suPAR circulating levels and renal impairment (RI) in newly diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Papassotiriou, Gerasimos-Petros, Kastritis, Efstathios, Margeli, Alexandra, Kanellias, Nikolaos, Eleutherakis-Papaiakovou, Evangelos, Migkou, Magdalini, Fotiou, Despina, Roussou, Maria, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Psimenou, Erasmia, Papassotiriou, Ioannis, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600599/
https://www.ncbi.nlm.nih.gov/pubmed/33022958
http://dx.doi.org/10.3390/jcm9103201
_version_ 1783603185325178880
author Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Papassotiriou, Gerasimos-Petros
Kastritis, Efstathios
Margeli, Alexandra
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Migkou, Magdalini
Fotiou, Despina
Roussou, Maria
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Psimenou, Erasmia
Papassotiriou, Ioannis
Dimopoulos, Meletios A.
author_facet Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Papassotiriou, Gerasimos-Petros
Kastritis, Efstathios
Margeli, Alexandra
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Migkou, Magdalini
Fotiou, Despina
Roussou, Maria
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Psimenou, Erasmia
Papassotiriou, Ioannis
Dimopoulos, Meletios A.
author_sort Terpos, Evangelos
collection PubMed
description (1) Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney disease in different disease settings. The aim of this study was to investigate a possible link between suPAR circulating levels and renal impairment (RI) in newly diagnosed patients with symptomatic multiple myeloma (NDMM) before and after frontline therapy with bortezomib-based regimens. (2) Methods: We studied 47 NDMM patients (57% males, median age 69.5 years) before the administration of anti-myeloma treatment and at best response to bortezomib-based therapy. suPAR was measured in the serum of all patients and of 24 healthy matched controls, using an immuno-enzymatic assay (ViroGates, Denmark). (3) Results: suPAR levels were elevated in NDMM patients at diagnosis compared to healthy individuals (p < 0.001). suPAR levels strongly correlated with disease stage (p-ANOVA < 0.001). suPAR levels both at diagnosis and at best response negatively correlated with estimated glomerular filtration rate (eGFR) values (p < 0.001). Interestingly, no significance changes in suPAR levels were observed at best response compared to baseline values (p = 0.31) among 18 responding patients with baseline eGFR < 50 mL/min/1.73 m(2). (4) Conclusions: SuPAR levels reflect renal function in NDMM patients treated with bortezomib-based induction. Responders may have elevated circulating suPAR levels, possibly reflecting persistent kidney damage, despite their renal response.
format Online
Article
Text
id pubmed-7600599
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76005992020-11-01 Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Papassotiriou, Gerasimos-Petros Kastritis, Efstathios Margeli, Alexandra Kanellias, Nikolaos Eleutherakis-Papaiakovou, Evangelos Migkou, Magdalini Fotiou, Despina Roussou, Maria Gavriatopoulou, Maria Malandrakis, Panagiotis Psimenou, Erasmia Papassotiriou, Ioannis Dimopoulos, Meletios A. J Clin Med Article (1) Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney disease in different disease settings. The aim of this study was to investigate a possible link between suPAR circulating levels and renal impairment (RI) in newly diagnosed patients with symptomatic multiple myeloma (NDMM) before and after frontline therapy with bortezomib-based regimens. (2) Methods: We studied 47 NDMM patients (57% males, median age 69.5 years) before the administration of anti-myeloma treatment and at best response to bortezomib-based therapy. suPAR was measured in the serum of all patients and of 24 healthy matched controls, using an immuno-enzymatic assay (ViroGates, Denmark). (3) Results: suPAR levels were elevated in NDMM patients at diagnosis compared to healthy individuals (p < 0.001). suPAR levels strongly correlated with disease stage (p-ANOVA < 0.001). suPAR levels both at diagnosis and at best response negatively correlated with estimated glomerular filtration rate (eGFR) values (p < 0.001). Interestingly, no significance changes in suPAR levels were observed at best response compared to baseline values (p = 0.31) among 18 responding patients with baseline eGFR < 50 mL/min/1.73 m(2). (4) Conclusions: SuPAR levels reflect renal function in NDMM patients treated with bortezomib-based induction. Responders may have elevated circulating suPAR levels, possibly reflecting persistent kidney damage, despite their renal response. MDPI 2020-10-03 /pmc/articles/PMC7600599/ /pubmed/33022958 http://dx.doi.org/10.3390/jcm9103201 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Papassotiriou, Gerasimos-Petros
Kastritis, Efstathios
Margeli, Alexandra
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Migkou, Magdalini
Fotiou, Despina
Roussou, Maria
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Psimenou, Erasmia
Papassotiriou, Ioannis
Dimopoulos, Meletios A.
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title_full Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title_fullStr Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title_full_unstemmed Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title_short Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
title_sort circulating soluble urokinase-type plasminogen activator receptor levels reflect renal function in newly diagnosed patients with multiple myeloma treated with bortezomib-based induction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600599/
https://www.ncbi.nlm.nih.gov/pubmed/33022958
http://dx.doi.org/10.3390/jcm9103201
work_keys_str_mv AT terposevangelos circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT ntanasisstathopoulosioannis circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT papassotiriougerasimospetros circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT kastritisefstathios circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT margelialexandra circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT kanelliasnikolaos circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT eleutherakispapaiakovouevangelos circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT migkoumagdalini circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT fotioudespina circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT roussoumaria circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT gavriatopouloumaria circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT malandrakispanagiotis circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT psimenouerasmia circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT papassotiriouioannis circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction
AT dimopoulosmeletiosa circulatingsolubleurokinasetypeplasminogenactivatorreceptorlevelsreflectrenalfunctioninnewlydiagnosedpatientswithmultiplemyelomatreatedwithbortezomibbasedinduction